Published in Mol Cancer Ther on February 01, 2005
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 3.66
A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ (2010) 2.25
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther (2008) 1.95
Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood (2008) 1.36
BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat (2007) 1.33
Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin Cancer Res (2008) 1.30
Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Phys (2009) 1.19
Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol (2008) 1.13
Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets (2010) 1.11
AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. Radiat Oncol (2009) 1.06
Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. Expert Opin Ther Pat (2011) 1.04
Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity. Exp Mol Med (2008) 1.00
(-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis. Mol Cancer Ther (2011) 0.94
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. Bioorg Med Chem (2010) 0.94
Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer. Am J Cancer Res (2011) 0.91
ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells. Cancer Res (2014) 0.90
Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation. Int J Radiat Oncol Biol Phys (2010) 0.88
Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro. Asian J Androl (2010) 0.86
Amphipathic tail-anchoring peptide and Bcl-2 homology domain-3 (BH3) peptides from Bcl-2 family proteins induce apoptosis through different mechanisms. J Biol Chem (2010) 0.86
Gossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-κB/AP-1 dependent- and independent-signaling. Clin Exp Metastasis (2011) 0.85
A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies. J Pharm Biomed Anal (2012) 0.83
Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (-)-gossypol. Asian J Androl (2010) 0.83
Radiosensitization in prostate cancer: mechanisms and targets. BMC Urol (2013) 0.81
Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway. Drug Des Devel Ther (2014) 0.81
Small-molecule inhibitors reveal a new function for Bcl-2 as a proangiogenic signaling molecule. Curr Top Microbiol Immunol (2011) 0.81
The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies. J Bioenerg Biomembr (2007) 0.79
F10 Inhibits Growth of PC3 Xenografts and Enhances the Effects of Radiation Therapy. J Clin Oncol Res (2015) 0.79
The BH3-mimetic gossypol and noncytotoxic doses of valproic acid induce apoptosis by suppressing cyclin-A2/Akt/FOXO3a signaling. Oncotarget (2015) 0.79
Examination of Gossypol-Pluronic Micelles as Potential Radiosensitizers. AAPS J (2015) 0.77
Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer. Radiat Oncol (2015) 0.77
WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. Cancer Res (2008) 0.77
Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models. Br J Cancer (2014) 0.77
Involvement of Bcl-2, Src, and ERα in gossypol-mediated growth inhibition and apoptosis in human uterine leiomyoma and myometrial cells. Acta Pharmacol Sin (2010) 0.76
Apogossypolone inhibits the proliferation of LNCaP cells in vitro and in vivo. Mol Med Rep (2014) 0.75
Molecular and Kinetic Characterization of Babesia microti Gray Strain Lactate Dehydrogenase as a Potential Drug Target. Drug Target Insights (2014) 0.75
Injectable (-)-gossypol-loaded Pluronic P85 micelles for cancer chemoradiotherapy. Int J Radiat Biol (2016) 0.75
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. J Med Chem (2004) 6.50
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J Comput Aided Mol Des (2002) 5.65
The PDBbind database: methodologies and updates. J Med Chem (2005) 5.53
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst (2012) 5.27
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 3.66
Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol (2009) 3.62
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol (2009) 3.47
A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A (2005) 3.46
Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal Biochem (2004) 3.02
Abrupt tropical climate change: past and present. Proc Natl Acad Sci U S A (2006) 2.97
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem (2006) 2.95
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol (2010) 2.90
Comparative evaluation of 11 scoring functions for molecular docking. J Med Chem (2003) 2.87
Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer (2003) 2.77
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat (2005) 2.75
Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology Group. J Clin Oncol (2014) 2.67
Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res (2006) 2.46
Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem (2006) 2.35
GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat (2005) 2.30
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol (2005) 2.25
Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry (2012) 2.20
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood (2007) 2.16
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol (2008) 2.15
Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc (2005) 2.12
Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res (2008) 2.04
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther (2008) 1.95
Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) (2007) 1.94
Mutations in the autoregulatory domain of β-tubulin 4a cause hereditary dystonia. Ann Neurol (2013) 1.90
Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol (2006) 1.88
SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res (2008) 1.87
Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem (2004) 1.87
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res (2006) 1.85
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
An extensive test of 14 scoring functions using the PDBbind refined set of 800 protein-ligand complexes. J Chem Inf Comput Sci (2004) 1.80
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol (2004) 1.72
Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res (2007) 1.71
Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther (2005) 1.70
Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc (2007) 1.70
A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Biol Ther (2008) 1.62
CSAR benchmark exercise of 2010: selection of the protein-ligand complexes. J Chem Inf Model (2011) 1.61
PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res (2012) 1.61
Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol (2003) 1.60
Structure-based design of potent, conformationally constrained Smac mimetics. J Am Chem Soc (2004) 1.60
A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys (2012) 1.60
Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther (2005) 1.60
Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI. Int J Radiat Oncol Biol Phys (2005) 1.59
A system for sharing routine surgical pathology specimens across institutions: the Shared Pathology Informatics Network. Hum Pathol (2007) 1.59
A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem (2011) 1.58
Personalized tamoxifen: what is the best way forward? J Clin Oncol (2011) 1.57
(alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. J Am Chem Soc (2007) 1.56
Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther (2008) 1.55
In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res (2004) 1.55
(-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia (2006) 1.55
Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol (2003) 1.55
Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J Med Chem (2006) 1.49
Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res (2003) 1.47
Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res (2002) 1.47
(-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther (2005) 1.45
Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res (2006) 1.43
CSAR benchmark exercise of 2010: combined evaluation across all submitted scoring functions. J Chem Inf Model (2011) 1.42
A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther (2013) 1.42
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics (2003) 1.39
Chimeric (alpha/beta + alpha)-peptide ligands for the BH3-recognition cleft of Bcl-XL: critical role of the molecular scaffold in protein surface recognition. J Am Chem Soc (2005) 1.39
Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol (2003) 1.36
Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem (2009) 1.34
Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol (2006) 1.33
Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res (2005) 1.32
Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin Cancer Res (2008) 1.30